Short Bowel Syndrome Pipeline Insight

Short Bowel Syndrome Overview

"Short Bowel Syndrome Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Short Bowel Syndrome market. A detailed picture of the Short Bowel Syndrome pipeline landscape is provided, which includes the disease overview and Short Bowel Syndrome treatment guidelines. The assessment part of the report embraces in-depth Short Bowel Syndrome commercial assessment and clinical assessment of the Short Bowel Syndrome pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Short Bowel Syndrome collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.


Short Bowel Syndrome of pipeline development activities 

The report provides insights into: 

  • All of the companies that are developing therapies for the treatment of Short Bowel Syndrome with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Short Bowel Syndrome treatment.
  • Short Bowel Syndrome key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Short Bowel Syndrome market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.  


Short Bowel Syndrome Analytical Perspective by DelveInsight

  • In-depth Short Bowel Syndrome Commercial Assessment of products 

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

  • Short Bowel Syndrome Clinical Assessment of products 

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.


Scope of the report

  • The Short Bowel Syndrome report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Short Bowel Syndrome across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Short Bowel Syndrome therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Short Bowel Syndrome research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Short Bowel Syndrome.


Report highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Short Bowel Syndrome.    
  • In the coming years, the Short Bowel Syndrome market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Short Bowel Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Short Bowel Syndrome treatment market. Several potential therapies for Short Bowel Syndrome are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Short Bowel Syndrome market size in the coming years.  
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Short Bowel Syndrome) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. 


Key Questions

  • What are the current options for Short Bowel Syndrome treatment?
  • How many companies are developing therapies for the treatment of Short Bowel Syndrome
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Short Bowel Syndrome?
  • How many Short Bowel Syndrome emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Short Bowel Syndrome?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies? 
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Short Bowel Syndrome market? 
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Short Bowel Syndrome?  
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Short Bowel Syndrome therapies? 
  • What are the clinical studies going on for Short Bowel Syndrome and their status?
  • What are the results of the clinical studies and their safety and efficacy? 
  • What are the key designations that have been granted for the emerging therapies for Short Bowel Syndrome
  • How many patents are granted and pending for the emerging therapies for the treatment of Short Bowel Syndrome

1. Report Introduction

2. Short Bowel Syndrome 

2.1. Overview

2.2. History 

2.3. Short Bowel Syndrome Symptoms

2.4. Causes

2.5.Pathophysiology

2.6. Short Bowel Syndrome Diagnosis 

2.6.1. Diagnostic Guidelines

3. Short Bowel Syndrome Current Treatment Patterns

3.1. Short Bowel Syndrome Treatment Guidelines

4. Short Bowel Syndrome - DelveInsight's Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Short Bowel Syndrome companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Short Bowel Syndrome Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Short Bowel Syndrome Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs 

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Short Bowel Syndrome Late Stage Products (Phase-III)

7. Short Bowel Syndrome Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Short Bowel Syndrome Discontinued Products

13. Short Bowel Syndrome Product Profiles

13.1. Drug Name: Company 

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition 

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

Detailed information in the report? 

14. Short Bowel Syndrome Key Companies

15. Short Bowel Syndrome Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products 

16.2.1. Reasons for the discontinuation

17. Short Bowel Syndrome Unmet Needs

18. Short Bowel Syndrome Future Perspectives

19. Short Bowel Syndrome Analyst Review  

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation 

Table 1: Short Bowel Syndrome Diagnostic Guidelines

Table 2: Short Bowel Syndrome Treatment Guidelines

Table 3: Assessment Summary

Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis

Table 5: Short Bowel Syndrome Acquisition Analysis

Table 6: Assessment by Phase of Development

Table 7: Assessment by Product Type (Mono / Combination)

Table 8: Assessment by Stage and Product Type

Table 9: Assessment by Route of Administration

Table 10: Assessment by Stage and Route of Administration

Table 11: Assessment by Molecule Type

Table 12: Assessment by Stage and Molecule Type

Table 13: Assessment by MOA

Table 14: Assessment by Stage and MOA

Table 15: Assessment by Target

Table 16: Assessment by Stage and Target

Table 17: Short Bowel Syndrome Late Stage Products (Phase-III)

Table 18: Short Bowel Syndrome Mid Stage Products (Phase-II)

Table 19: Short Bowel Syndrome Early Stage Products (Phase-I) 

Table 20: Pre-clinical and Discovery Stage Products

Table 21: Inactive Products

Table 22: Dormant Products

Table 23: Discontinued Products

Figure 1: Disease Overview

Figure 2: History

Figure 3: Symptoms

Figure 4: Causes

Figure 5: Pathophysiology

Figure 6: Diagnostic Guidelines

Figure 7: Treatment Guidelines

Figure 8: Short Bowel Syndrome companies collaborations, Licensing, Acquisition -Deal Value Trends

Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis

Figure 10: Short Bowel Syndrome Acquisition Analysis

Figure 11: Assessment by Phase of Development 

Figure 12: Assessment by Product Type (Mono / Combination)

Figure 13: Assessment by Stage and Product Type

Figure 14: Assessment by Route of Administration

Figure 15: Assessment by Stage and Route of Administration

Figure 16: Assessment by Molecule Type

Figure 17: Assessment by Stage and Molecule Type

Figure 18: Assessment by MOA

Figure 19: Assessment by Stage and MOA

Figure 20: Late Stage Products (Phase-III)

Figure 21: Mid Stage Products (Phase-II)

Figure 22: Early Stage Products (Phase-I)

Figure 23: Pre-clinical and Discovery Stage Products

Figure 24: Inactive Products

Figure 25: Dormant Products

Figure 26: Discontinued Products

Figure 27: Unmet Needs

  • Tags:
  • Short Bowel Syndrome Pipeline
  • Short Bowel Syndrome clinical trial...
  • Short Bowel Syndrome companies
  • Short Bowel Syndrome drugs
  • Short Bowel Syndrome therapies
  • Short Bowel Syndrome treatment algo...
  • Short Bowel Syndrome pipeline drugs
  • Short Bowel Syndrome pipeline compa...

Forward to Friend

Need A Quote